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Breast Cancer and Lymphedema: A Narrative Review 
Athena Michaelides,1 Constantina Constantinou.2 
Abstract 
Breast cancer is the second most common cancer diagnosed worldwide, and the leading cause of cancer death in women. The understanding of disease 
presentation by patients and health care providers is crucial for a correct diagnosis and management.  Preventive measures emphasize risk-reducing 
behaviors such as a healthy diet, reduced alcohol consumption, increased physical activity, and breastfeeding children. Screening techniques such as 
mammography, ultrasound, and MRI aid in early detection. Following the screening, a breast biopsy is performed, and a histopathological assessment is 
carried out to confirm a breast cancer diagnosis. In addition to surgery, radiotherapy, and lifestyle modifications, treatment regimens include a range of 
medications such as anti-hormonal drugs and chemotherapy. Lymphedema is a severe and major long-term consequence of breast cancer treatment. The 
major contributors to the diminished lymph drainage are a lumpectomy/mastectomy procedure that involves the surgical removal of lymph nodes, and 
radiotherapy. The fluid accumulation of lymphedema poses physical limitations to the patient and impacts the overall quality of life. A sentinel lymph 
node biopsy is an essential method of identifying the first draining lymph nodes affected by metastasis. This procedure allows surgeons to later remove 
only affected lymph nodes, sparing those that are unaffected and hence reduce the risk and magnitude of lymphedema development. Patients who receive 
education about lymphedema demonstrate higher compliance with treatment and self-care management practices. The purpose of this review is to provide 
information about breast cancer, the development of lymphedema, and how to recognize and manage both. 
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Introduction 
Cancer is a disease process characterized by abnormal cell growth that 
can affect any part of the body. Benign tumors are confined to one part 
of the body, whilst malignant tumors spread via the blood or 
lymphatics to other parts of the body.1 Amongst all cancer types, the 
most common is breast cancer (24.2%), followed by colorectal (9.5%), 
and lung cancer (8.4%). Of a total 4.2 million cancer deaths, breast 
cancer is the leading cause of cancer deaths in women (15%), followed 
by lung cancer (13.8%) and then colorectal cancer (9.5%).2 
 
The mechanism of cancer development varies according to cancer type 
and origin, and the characteristics of the affected individual. Breast 
cancer development is mostly influenced by the presence of estrogen 
and progesterone hormones in the circulation giving rise to hormone 
receptor-positive breast cancer.3 Less commonly, hormone receptor-
negative cancer may arise. Other mechanisms include mutations in 
tumor suppressor genes, some of which are hereditary such as BRCA1 
and BRCA2.4  
 
Its widespread burden emphasizes the importance of screening, correct 
diagnosis, and treatment. The history and physical examination of the 
patient are important in the initial identification of suspected 
pathologies.4 Imaging techniques such as mammography, ultrasound, 
MRI and CT have a role in further investigation of any abnormal 
findings.5 The pathological findings detected through imaging are taken 
a final step further with a breast tissue biopsy providing the final 
diagnosis.6  
 
Breast cancer is categorized according to 3 major classification systems: 
the histopathology of biopsied specimens, grade, or stage.7 Each 
system establishes a final level of cancer spread and severity that 
determines the treatment regimen and predicted prognosis. Further to 
classification, presenting symptoms are organized into clusters, with 
clusters of increased symptom number and severity foreshadowing a 
worse prognosis.8 According to the incidence rates of organs typically 
affected, the metastasis of breast cancer affects lymph nodes (64%), 
lungs (57%), red bone marrow (55%), liver (51%), bone (49%), adrenals 
(34%), and the brain (10%).9 Over 90% of women who develop breast 
cancer, have what is referred to as ‘early breast cancer’ in which cancer 
is confined to the breast and axillary lymph nodes.10 Since the lymph 
nodes are the primary site of cancer spread, the impact of lymph node 
removal is an appropriate point of further discussion. 
 
As part of the treatment process, affected lymph nodes (and sometimes 
unaffected lymph nodes) are removed during lumpectomy/mastectomy 
surgeries.11 Due to the reduced capacity of the remaining lymph nodes 
to remove excess interstitial fluid, lymphedema develops as a 
consequence and affects between 12-28% of women treated for breast 
cancer.12 Lymphedema may also occur after radiotherapy due to the 
formation of scar tissue impeding lymph flow. Lymphedema presents 
as swelling of the affected arm that involves pain, heaviness and a 
disrupted functioning of everyday tasks.11 It may progress to a more 
severe fibrotic process and soft tissue destruction that manifest as 
warts, tissue bulges and open wounds.13  
 
The management of lymphedema includes a range of compression 
therapies and physical therapy.14 Because a large portion of treatment 
involves self-care practices, it is crucial that the patient is adherent, 
and has access to information regarding the therapeutic process and 
progress.15 
 
Since breast cancer is a significant contributor to the overall burden of 
cancer, and its treatment is a recognized contributor to lymphedema, 
the link between breast cancer treatment and lymphedema is proven 
to be a valuable topic for research. The purpose of this literature review 
is to provide a basic understanding of the principles of breast cancer 
and lymphedema to patients, medical professionals, and the general public. 
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Papers were extracted from the PubMed database using varying 
combinations of the search terms breast cancer or breast carcinoma; 
presentation; diagnosis; classification; pathogenesis; management; and 
prevention. A second search that focused on the development of 
lymphedema included combinations of the search terms lymphedema; 
consequence; breast cancer; surgery; radiotherapy; diagnosis; 
classification; pathogenesis; management; and prevention. Papers were 
limited to human subjects, and the English language. Small-scale 
studies that were inconclusive or had results of no statistical 
significance were excluded. The literature was screened for the 
information considered to be most up-to-date and relevant to medical 
professionals and the wider public. The information was then extracted 
and summarized to be used for this review. 
 
Presentation 
With the development of screening techniques such as mammography 
and other imaging modalities, breast cancer is usually detected prior 
to the development of obvious signs and symptoms. However, the signs 
and symptoms that may become apparent to the patient still pose as 
an important area of discussion. A first sign of breast cancer that is 
usually noticed by the patient is a lump in the breast that feels different 
to the surrounding tissue.16 A change in shape, size and general breast 
appearance may be noted.1 Further skin changes reveal skin erythema, 
peeling, scaling, and a characteristic dimpling resembling that of an 
orange peel known as peau d’orange.1  
 
Nipple changes are often unilateral and include distortion, inversion, 
retraction or elevation, and eczematous skin changes from the nipple 
and surrounding areola that is unresponsive to topical treatment.1  The 
nipple may also secrete a serous or bloody discharge.17 If the cancer 
has spread to the lymph nodes, pain and swelling around the clavicles 
and axilla may be present.1  
 
Symptoms often present concurrently in breast cancer patients.8 The 
total burden of symptoms shows a negative correlation with the quality 
of life, with every additional symptom relating to a further decline.8 
Symptoms include physiological disturbances as well as psychological 
effects. The physiological aspect includes pain, numbness, disturbed 
sleep, decreased sex drive, weight changes, peripheral neuropathy, 
gastrointestinal disturbance, and spontaneous menopause.8-9 The 
psychological symptoms include fatigue, anxiety, depression, perceived 
cognitive impairment, mood changes, and a lowered self-esteem.9 
 
Diagnosis 
Patient history and physical examination 
The patient’s history and physical examination establish the link 
between risk factors and symptomatology. Clinical history assesses the 
risk of cancer and includes questions regarding the age of menarche, 
pregnancies to date, menopausal status, and medications such as oral 
contraceptive and hormone replacement therapy. A family history of breast 
and ovarian cancer in first degree relatives should also be established.18 
 
As part of the physical examination, the patient is first positioned 
sitting upright with the upper body exposed so that a thorough 
inspection can be carried out to identify breast asymmetry, nipple 
changes and discharge, and visible masses. Specific skin changes to 
look out for include skin erythema, dimpling, and peau d’orange. 
Palpation of the breast parenchyma then proceeds with the patient in 
the supine position and ipsilateral arm placed over the head. Cervical, 
supraclavicular and axillary lymph nodes are also palpated for signs of 
lymphadenopathy.18 
 
Imaging techniques  
To further investigate suspicions of breast cancer, a range of imaging 
techniques are utilized. The American Cancer Society (ACS) 
recommends mammography as the primary mass screening technique 
for females between the ages of 40 and 74. However, the ionizing 
radiation poses a limitation to its widespread use especially in pregnant 
females in which mammography is contraindicated. False-positive and 
false-negative results also limit mammography as a diagnostic tool in 
patients.5 Mammography has a false-negative result of about 13%. The 
chance of having a false-positive result ranges from 7-12%, with 
younger women and women with dense breasts being more likely to 
have a false-positive result.5  
 
Breast ultrasound (US) is used as a supplement to mammography to 
improve sensitivity. In using acoustic waves to reflect breast structures, 
cysts and solid masses can be identified.19 However, healthy and 
cancerous tissue may present similar acoustic properties that 
ultrasound may fail to differentiate between.5 
 
Magnetic resonance imaging (MRI) is non-invasive and non-ionizing, 
making it ideal for high risk patients who cannot undergo other 
screening and diagnostic procedures. Magnetic fields with radio 
frequency signals are applied to create cross-sectional images for the 
identification of tumor masses.17  High costs, lack of availability, time 
consumption, and its high false-positive rate limit the widespread use 
of MRI.5 It is also difficult to detect some types of cancers such as 
invasive ductal and lobular carcinoma using MRI, but it has a role in 
the identification of distant metastasis.  
 
Computer tomography (CT) uses radioactive waves to provide cross-
sectional images from different angles of the body. It provides images 
of soft tissue, bone, and blood vessels, making it is useful for 
determining distant metastasis. However, CT has a low sensitivity and 
poses a radiation risk.5 Position emission tomography (PET) involves 
the administration of a radioactive isotype and the detection of photons 
produced during the process of radioactive decay that interact with 
surrounding tissue.20 PET is used for imaging distant metastasis and 
response to therapy. The use of ionizing radiation as well as a 
radioactive tracer limit its widespread use.5 
 
Breast biopsy and fine needle aspiration  
After relevant imaging of the patient’s breast, the final diagnosis is 
made based on the results of a biopsy. This involves removing cells 
from the breast tissue to be examined in a laboratory in order to 
identify abnormalities.6 The literature describes surgical biopsy as the 
gold standard for breast diagnosis before the 1990’s.6 This subjected 
the patient to a cumbersome process and an invasive surgery which 
proved to be unnecessary in some cases.  
 
As an advancement, percutaneous needle biopsy (PNB) emerged as the 
preferred method of breast diagnosis. Fine needle aspiration biopsy 
(FNAB) was the first to emerge in this category.6 Following FNAB, the 
introduction of the image directed core needle biopsy revolutionized 
the field with its ability to obtain histological samples that provide 
diagnostic information not achieved by FNAB. It can distinguish invasive 
from non-invasive cancer, determine tumor grade, and expression of 
hormone receptors.6 
 
The full extent of the disease can be assessed before surgery by 
sampling areas susceptible to cancer spread. The surgeon may request 
that a sentinel lymph node biopsy (SLNB) be performed to investigate 
the extent of metastasis to nearby lymph nodes.6 A radioactive 
substance or a dye are injected near the tumor. The first few lymph 
nodes that drain the breast tissue will absorb the radioactive substance 
and be detected by a probe. These lymph nodes can then be removed 
and checked for cancerous cells.21 Further to this, a decision can be 
made regarding the extent of lymph node removal based on whether 
cancerous cells are present or not. 
 
Classification 
Tumors are mostly classified according to the histopathological features 
of biopsied specimens that are viewed under light microscopy.7 Looking 
at the growth patterns and cytological features, two main categories of 
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breast cancer have been described: carcinoma in situ; and invasive 
(infiltrating) carcinoma. Breast carcinoma in situ is further classified as 
either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ 
(LCIS).22 DCIS is the more common subtype and is sub-classified even 
further into five distinct types based on architectural features: comedo; 
cribriform; micropapillary; papillary; and solid. Invasive (infiltrating) 
carcinoma is further classified as: tubular; ductal lobular; invasive 
lobular; infiltrating ductal; mucinous (colloid); medullary; and 
infiltrating ductal.22  
 
Another system classifies cancer according to grade and focuses on the 
appearance of cancer cells compared to normal tissue. The Scarff-
Bloom-Richardson grading system allocates scores to features of breast 
tissue that include tubule formation, nuclear polymorphism, and 
mitotic count. The overall score classifies the tumor as grade 1 (well-
differentiated, good prognosis), grade 2 (moderately differentiated, 
medium prognosis), or grade 3 (poorly differentiated, worse prognosis).23  
 
The third system classifies cancer according to the stage, and follows 
the TNM (tumor, lymph node involvement, and metastasis) system. 
This system describes the severity of cancer and assists with the 
selection of appropriate treatment in conjunction with other factors 
such as the presence of estrogen and progesterone receptors.24  
 
The Breast Imaging Report and Data System (BI-RADS) is a 
communication tool described by the American College of Radiology 
(ACR) to reduce variability when creating mammography, ultrasound, 
and MRI reports.  It uses a standardized approach to define the features 
of a breast mass by detailing the density, location, 
micro/macrocalcifications, architectural distortions, and associated 
findings.25 By doing this, BI-RADS aids in the reproducibility and 
comparison of radiological descriptions of breast cancer findings. Table 
1 describes the BI-RADS classification in more detail. 
 
Pathogenesis 
The pathogenesis of breast cancer is variable across populations as it 
depends on an interaction between environment, lifestyle, and genetic 
susceptibility.18 Several mechanisms contribute to the unchecked 
proliferation of breast tissue. 
 
Hormone receptor-positive breast cancer (ER+ and PR+) 
Estrogen and progesterone are central in regulating the growth and 
differentiation of mammary glands.3 The effects of estrogen are 
mediated through its binding to estrogen receptors ER-a and ER-b, and 
those of progesterone to the progesterone receptor (PR).3 Although the 
exact mechanism is not understood, the binding of estrogen and 
progesterone to their respective receptors on cancerous cells, leads to 
altered gene activity and uncontrolled ER- or PR-mediated breast tissue 
proliferation.26 Approximately 80% of all cancers are ER-positive, and 
65% of these are also PR-positive. The age-specific statistics suggest 
that there is an increased incidence rate of breast cancer before 
menopause (ages 40-50) that tends to slow down after this probably 
due to the decreased levels of circulating estrogens produced by the 
ovaries.27 However, sources of these hormones are also exogenous in 
the form of the oral contraceptive pill (in pre-menopausal women) or 
hormone replacement therapy (in post-menopausal women).26 An 
increased risk of breast cancer has been established in women who 
take these medications.26-28 
 
HER-2 overexpression  
HER-2 (human epidermal growth factor 2), otherwise known as ERBB2 
(Erb-B2 receptor tyrosine kinase 2) is a receptor tyrosine protein kinase 
found on breast cells that accounts for 25-30% of breast cancers when 
overexpressed.29 Under normal conditions, this receptor is found on 
breast cells to stimulate breast development.29  
 
 
 
Table 1. BI-RADS Classification.25 
 
Category Explanation Chance of malignancy Action 
0 Incomplete 
evaluation 
N/A Further imaging 
required 
1 Negative 
examination. No 
masses, suspicious 
calcifications, or 
areas of architectural 
distortion  
0% Normal interval 
follow-up  
2 Benign. Secretory 
calcifications, simple 
cysts, fat containing 
lesions, calcified 
fibroadenomas, 
implants, and 
intramammary lymph 
nodes  
0% Normal interval 
follow-up 
3 Probably benign. 
Non-palpable 
circumscribed mass 
on baseline 
mammogram, a focal 
asymmetry, or a 
solitary group of 
punctate 
calcifications  
<2% Shortened interval 
follow-up  
4 Suspicious findings A – 2-10% 
B – 10-50% 
C – 50-95% 
Biopsy considered  
5 Highly suggestive of 
malignancy 
>95% Biopsy or surgery 
6 Proven malignancy  N/A Imaging for cancer 
staging or 
evaluation after 
chemotherapy  
 
Legend: Derived from ‘BIRADS classification in mammography’ European Journal 
of Radiology 61(2007) pp. 192-194.25 
 
Tumor suppressor gene mutations 
The PI3K/AKT pathway is important in regulating the cell cycle by 
initiating downstream survival signals that protect the cell from 
premature death.30 This pathway is regulated by the tumor suppressor 
protein, PTEN, that turns off the PI3K/AKT by initiating apoptosis when 
conditions are appropriate.31 Mutations in PTEN lead to a constantly 
activated PI3K/AKT pathway that in effect causes inappropriate proliferation.31  
 
Five percent of breast cancer cases are attributed to genetic mutations 
in the tumor suppressor genes BRCA1 and BRCA2.18-32 Of the hundreds 
of mutations identified, some have no impact, while others are involved 
in the development of hereditary breast-ovarian cancer syndrome that 
is responsible for breast and ovarian cancer in genetically related families.33 
 
Management 
The management and treatment of breast cancer vary according to 
disease type and severity, age, the overall health of the patient, and 
personal treatment preference.34 In the early stages, local therapy such 
as surgery and radiotherapy are effective, whereas in advanced and 
metastatic cases, systemic therapy is preferred.35 Compared to age-
matched women without the disease, the 5-year survival of women 
with breast cancer has increased from 80% in the 1950’s to 89% today.11 
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Surgery & Radiation Therapy  
The initial management of breast cancer is surgery.34 A more 
conservative lumpectomy (solitary lump removal), is the preferred 
surgical therapy when the tumor is smaller than 4cm in size.36 A 
mastectomy (complete breast resection) is the treatment of choice 
when the patient presents with tumors in different breast areas, tumors 
that are large in relation to the breast, instances where radiotherapy in 
inaccessible to the patient, or when the patient requests to avoid 
systemic therapy.36  
 
During the mastectomy surgery, axillary lymph nodes may also be 
removed to determine the extent of metastasis. These changes affect 
the lymph drainage of the ipsilateral arm, leading to lymphedema.11 
 
Radiation therapy serves as an adjunct to lumpectomy and mastectomy 
surgeries, as a means of reducing local cancer recurrence.35 Radiation 
therapy uses high energy X-rays or gamma rays to eradicate cancerous 
cells that either recur after tumor removal, or remain after surgery.37  
External beam radiation is the most common type of radiotherapy that 
utilizes energy from a machine exterior to the body.37 
 
Due to the high intensity of the radiation, normal tissue surrounding 
cancerous tissue is also damaged. However, healthy tissue has a repair 
response that cancer cells lack, so radiation therapy is given over an 
extended period of 5-7 weeks to allow for recovery of the normal 
tissue.35 Patients may experience fatigue, muscle stiffness, swelling, or 
tenderness during the treatment period as well as a change in skin 
color resembling that of a sunburn.37 Similar to mammography, due to 
the high energy radiation, this therapy is contraindicated in pregnant 
patients.35  
 
Development of Lymphedema  
Under normal conditions, the role of the lymphatic system is to 
maintain fluid balance in tissues, fight infection and remove cellular 
debris from extracellular spaces. The venules reabsorb 90% of fluids 
that are filtered from the capillaries into the interstitium - the 
remaining 10% of fluid and proteins are removed by the lymphatic 
vessels to be returned to the bloodstream.11 The lymphatic system thus 
balances the inward and outward flow, creating a stable overall 
interstitial pressure. A disruption of this balance results in lymphedema 
- an abnormal accumulation of interstitial fluid that leads to chronic 
inflammation and possible fibrosis.38   
 
Lymphedema in the context of breast cancer is secondary to 
therapeutic interventions such as the resection of axillary lymph nodes 
or radiation therapy.38 Lymph node removal compromises the overall 
drainage capacity of the lymphatic system. Superficial scarring 
following surgery or scarring post-radiotherapy may impede the 
lymphatic flow across the scar tissue leading to fluid accumulation 
proximal to the scar.11 Localized post-surgery infection also leads to an 
increased volume of fluid and cellular components that may exceed the 
transport capacity of the impaired lymphatic system.10  
 
Areas commonly affected by the diminished lymph flow are those that 
generally drain to the axilla such as the ipsilateral breast, chest, upper 
trunk, arm, and hand.11 Increased age (>60 years), obesity (BMI >25), 
and a more extensive axillary lymph node dissection are associated 
with an increased risk of post-operative lymphedema.38  
 
Hayes et al., conducted a study in which 33% of women developed 
lymphedema 6-18 months after breast cancer surgery.39 A greater odds 
were associated with older age, treatment complications, and more 
extensive surgery (axillary node dissection, mastectomy, greater 
number of lymph nodes removed).39 The risk of developing 
lymphedema post-radiotherapy is directly related to the radiation dose. 
The combination of surgery and radiotherapy poses an even higher 
risk.38 Having a partner and partaking in regular activity was associated 
with a lower odds of lymphedema development.39  
The typical presentation of lymphedema after breast cancer is local 
swelling in one or both arms.13 Typical symptoms accompanying this 
include pain, heaviness, limited range of motion, and disruption of 
daily function - in particular, tasks involving gross and fine motor 
skills.13 Early signs include swelling that pits with applied pressure. As 
the disease progresses, patients may present with fibrosis and fat 
accumulation in the affected area. Warts, skin folds and papules may 
present at later stages.40 The patient may complain of impaired mobility 
and notice physical changes such as clothing or jewelry being too tight, 
difficulty writing, arm/hand puffiness, indentations, firm or leathery 
skin, and swelling after exercise.39  
 
Unlike breast cancer diagnosis, there is uncertainty around 
lymphedema diagnosis amongst physicians. However, diagnosis is 
commonly made upon a measurable 2cm (or more) difference in arm 
circumference or 200mL difference in limb volume between affected 
and non-affected limbs.11 A range of diagnostic evaluations have been 
identified to confirm lymphedema. Soft tissue imaging such as MRI, 
computed tomography (CT), and ultrasound assist in the detection of 
excess interstitial fluid. Lymphoscintigraphy, a nuclear medicine 
technique that images lymph vessels and nodes, detects slow or absent 
lymph flow. Bio-impedance spectroscopy (BIS) measures water content 
in tissues and has been especially useful in diagnosing breast cancer 
related lymphedema.41  
 
Lymphedema progression can be established by examining tissue 
changes that are categorized into three stages: Stage I is characterized 
by pitting upon application of pressure that subsides with limb 
elevation. Stage II is characterized by increased fibrosis and fat 
accumulation that no longer pits with applied pressure and does not 
subside with limb elevation. Stage III represents fibrotic progression 
that encompasses a range of soft tissue manifestations such as warts, 
skin folds and papules that lead to impaired mobility and infection 
susceptibility.40  
 
Two principal methods for managing breast cancer-related lymphedema 
are described: complex decongestive therapy (CDT); and exercise.14 CDT 
is divided into two parts: an intensive phase which consists of four 
components, and a maintenance phase in which the patient practices 
self-care with occasional manual lymph drainage (MLD) by a therapist.  
 
The four parts of the intensive phase include MLD, arm and shoulder 
exercises, compression therapy, and deep-breathing practices that 
promote venous and lymphatic flow.14 Exercise for patients with 
lymphedema follows supervised programs with goals to restore range 
of motion (ROM) and upper limb function, increase muscle strength, 
and to control swelling.14 Reduction in weight also helps lessen 
lymphedema.42  
 
Educating patients about secondary lymphedema, and subsequent 
management should not be underestimated. Many patients report not 
having received sufficient information about lymphedema as a 
complication of breast cancer.43 The use of lymph drainage massage 
services and compression garments was found to be utilized more 
amongst women who had received lymphedema education.15 A positive 
correlation between patient education and adherence to lymphedema 
therapy is demonstrated, emphasizing the importance of patient 
education.14  
 
Lymphedema prevention can be divided into pre-surgery and post-
surgery techniques. Already mentioned as part of diagnostic 
techniques, a sentinel lymph node biopsy is the most important 
method of identifying lymph node metastasis.44-45 Through identifying 
the axillary lymph nodes most likely to be affected by tumor 
metastases, it is possible to avoid unnecessary nodal dissection and 
hence lymphedema as a consequence.45 This benefit is proven in a 
meta-analysis showing the rate of lymphedema as a complication 
following axillary dissection is four times higher than following sentinel 
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node biopsy.46 Further to this, chemotherapy shows a protective effect 
against lymphedema development: 20-40% of node-positive patients 
tested node-negative after chemotherapy, so a sentinel node biopsy 
performed after chemotherapy could reduce unnecessary axillary 
dissection.46  
 
Due to the difficulty in predicting populations at risk for developing 
lymphedema after undergoing breast cancer surgery, clinicians 
recommend risk-reducing behavior as the primary preventative 
measure in all patients undergoing axilla surgery.47 The most widely 
recognized of these is the avoidance of venipuncture, injections, or 
taking blood pressure on the side of the affected arm, as well as the 
use of compression sleeves for air travel.47  Women who receive 
lymphedema education prior to treatment, exercise regularly, and 
implement preventative self-care activities demonstrate a lower 
incidence of lymphedema following breast cancer surgery.14, 48  
 
Systemic therapy 
Systemic therapy treats cancer cells throughout the body using a range 
of medications and is subdivided into chemotherapy, endocrine 
(hormone) therapy, and targeted therapy.34-35 The National Institute for 
Health Care Excellence (NICE) guidelines describe the populations in 
which chemotherapy is indicated. Adjuvant anthracycline-taxane 
combination chemotherapy is recommended in patients with invasive 
breast cancer who are at risk of disease recurrence. Neoadjuvant 
chemotherapy is offered to reduce the tumor size in patients with ER- 
invasive breast cancer and is considered in patients with ER+ invasive 
breast cancer. Neoadjuvant chemotherapy is given in combination with 
trastuzumab in patients with HER2+ invasive cancer.34 
 
NICE recommend that docetaxel is given as single-agent first-line 
therapy; vinorelbine or capecitabine as single-agent second-line 
treatment; vinorelbine or capecitabine (whichever was not used as 
second-line treatment) as single-agent third line treatment.34 
Alternative options for second-line treatments are Everolimus and 
Fulvestrant, and a third line alternative is Eribulin.34 Chemotherapy side 
effects include nausea and vomiting, hair loss, fatigue, mouth ulcers, 
dry and cracked skin, depression, weight changes, and an unpleasant 
taste in the mouth.  
 
Endocrine therapy is indicated for patients with ER+ tumors, and is 
administered after surgery, radiotherapy, and chemotherapy with the 
purpose of preventing relapse.48 Tamoxifen, which acts by inhibiting 
estrogen receptors, is the medication of choice for pre-menopausal 
women.34, 48 Aromatase inhibitors (either steroidal or non-steroidal) that 
act by lowering the amount of circulating estrogen are indicated for 
post-menopausal women.34 Patients who experience hot flushes as an 
adverse effect of hormone therapy, can reduce this by avoiding triggers 
such as caffeine, alcohol, and smoking. In cases where symptoms 
persist, serotonin-norepinephrine receptor inhibitors (SNRIs) such as 
venlafaxine may be administered.49  
 
Trastuzumab (otherwise known as Herceptin) in combination with 
paclitaxel is the medication of choice for tumors that are hormone 
receptor-negative and HER2-positive.34 Trastuzumab in a monoclonal 
antibody that blocks HER2 protein activity in breast cancer cells and 
hence halts tumor growth.29. 
 
Prevention 
Since the leading risk factor for developing breast cancer stems from 
prolonged exposure to endogenous hormones, it is not easily 
modifiable.51 Primary prevention of breast cancer is achieved by 
partaking in physical activity, maintaining a healthy weight, following 
a healthy diet, minimizing alcohol consumption, breastfeeding children, 
and minimizing the use of oral contraceptive pills and hormone 
replacement therapy.51 Testing for BRCA1 and BRCA2 mutations is 
recommended in women with affected family members.52 A bilateral 
mastectomy may be performed as prophylaxis for women who test 
positive for the mutations which are associated with increased risk of 
breast cancer.52  
 
Estrogen receptor antagonists such as tamoxifen reduce the risk of 
breast cancer, but at the expense of an increased risk of endometrial 
cancer and thromboembolic events.53 Because of this, they are reserved 
for treatment, and prevention only in high risk women.53 
 
Conclusion  
It is evident from the literature that breast cancer is a prevalent disease 
that affects women on a worldwide scale. It is also thoroughly 
described that breast cancer presents itself through a range of physical 
symptoms and clinical findings. This emphasizes the importance of 
screening techniques that aid in the early detection of the disease, and 
preventive measures. The limitations posed by each imaging technique 
(mammography, ultrasound, and MRI) suggest that each patient needs 
to be considered on an individual basis to select the most suitable 
method per patient. Treating breast cancer follows a similar 
individualized method, considering the mechanism of cancer 
pathogenesis through assessing hormonal exposure and gene 
overexpression.  
 
Because breast cancer is in most cases confined to the breast and 
axillary lymph nodes, the adverse effects that arise through lymph node 
resection are just as crucial as the adverse effects that arise through 
breast resection. Functional impairment, psychological distress, and 
disturbed daily routine are some of the significant effects of 
lymphedema that require management. The literature provides 
evidence that effective lymphedema management relies on the 
patient’s will to comply with self-care practices. For this reason, patient 
education is crucial.  
 
Continuous research and development are underway to develop highly 
specific treatment regimens that target breast cancer on a molecular 
genetic level. The advancement of the sentinel lymph node biopsy also 
has positive implications for reducing lymphedema as a complication 
of breast cancer metastasis and treatment. This suggests a promising 
overall prognosis for the general female population moving forward.  
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